First Patients Dosed in jCyte’s Phase II JC02-88 Trial for Retinitis Pigmentosa
jCyte turns up the dose, chasing broader answers for a disease with few options. A higher dose, a broader target…
Alcon to Acquire LumiThera, Expanding into Dry AMD Treatment
PBM therapy meets eye care giant muscle in Alcon’s latest AMD acquisition. Alcon (Geneva, Switzerland) is turning up the brightness…
popular posts
latest posts
